HR.4332 Generic Drug Application Review Fairness Act of 2012
To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act to extend the period for a first applicant, with respect to a generic drug, to obtain tentative approval without forfeiting the 180-day exclusivity period, and for other purposes.
- People's Vote
- YES
- Gov Vote
- NONE
- Outcome
- NONE
Recent Member Votes
My Representatives
Sponsored by
Copy and paste the code below to embed this bill:
Our Analysis:
Votetocracy has not yet analyzed this bill because it has not been considered after being introduced. For a more information please see the official summary below
Summary:
3/29/2012--Introduced.Generic Drug Application Review Fairness Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to extend from 30 to 60 months after application the period for a first applicant of a generic drug to obtain tentative approval without forfeiting the 180-day exclusivity period with respect to such drug, unless the failure in meeting the extended period is caused by a change in or review of approval requirements. Limits extension coverage to applications filed within 30 months preceding the enactment of this Act. Reduces such extended period by six months per year over a five-year period, beginning on October 1, 2013. Directs the Secretary of Health and Human Services (HHS) to maintain the Office of Generic Drugs as a separate office within the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA).
Actions:
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Question:
Result